AIZ
73
4
ESS
65
5
VFC
62
-3
PSA
60
5
DLTR
31
-3
PBI
59
-4
KIM
73
4
PG
48
7
KMB
30
2
GOOG
71
-6
SCHW
56
3
GIS
28
2
UNH
67
3
HD
54
5
USB
53
3
KHC
17
8
CMCSA
53
-11
LOW
56
3
KR
52
2
HSIC
45
11
AIZ
73
4
ESS
65
5
VFC
62
-3
PSA
60
5
DLTR
31
-3
PBI
59
-4
KIM
73
4
PG
48
7
KMB
30
2
GOOG
71
-6
SCHW
56
3
GIS
28
2
UNH
67
3
HD
54
5
USB
53
3
KHC
17
8
CMCSA
53
-11
LOW
56
3
KR
52
2
HSIC
45
11
Financhill
Back

VYNE Therapeutics Quote, Financials, Valuation and Earnings

The Mysterious VC Firm Behind Nvidia's Secret Weapon

Details Here!
Buy
60

VYNE
VYNE Therapeutics

Last Price:
3.14
Seasonality Move:
-9.41%

7 Day Trial

ALL ACCESS PASS

$ 7

U.S. Government Report Alert Tuesday

Discover the Secret Loophole

VYNE Therapeutics Price Quote

$3.14
-0.02 (-0.48%)
(Updated: November 9, 2024 at 5:52 AM ET)

VYNE Therapeutics Key Stats

Buy
60
VYNE Therapeutics (VYNE) is a Buy
Day range:
$3.11 - $3.25
52-week range:
$1.57 - $4.48
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
166.69
P/B ratio:
0.62%
Volume:
75.7K
Avg. volume:
104.5K
1-year change:
-6.78%
Market cap:
$46.6M
Revenue:
$424K
EPS:
$-2.82

How Much Does VYNE Therapeutics Make?

Is VYNE Therapeutics Growing As A Company?

  • What Is VYNE Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 0.47%
  • What Is VYNE Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

VYNE Therapeutics Stock Price Performance

What Is VYNE Therapeutics 52-Week High & Low?

VYNE Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy VYNE Therapeutics?

  • How Much Debt Does VYNE Therapeutics Have?
    Total long term debt quarterly is $0
  • How Much Cash Does VYNE Therapeutics Have?
    Cash and short term investments quarterly total is $78.1M
  • What Is VYNE Therapeutics’s Book Value Per Share?
    Book value per share is 5.15

Is VYNE Therapeutics Cash Flow Positive?

  • What Is VYNE Cash Flow From Operations?
    Cash flow from operations (TTM) is -$26.8M
  • What Is VYNE Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $82.6M
  • What Is VYNE Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$46.9M

VYNE Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    VYNE return on invested capital is -51.55%
  • What Is VYNE Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is -44.39%
  • What Is VYNE Return On Equity?
    ROE is a measure of profitability and is -51.55%

VYNE Therapeutics Earnings Date & Stock Price

VYNE Therapeutics Competitors

  • Who Are VYNE Therapeutics's Competitors?
    Below is a list of companies who compete with VYNE Therapeutics or are related in some way:
    • iBio Inc (IBIO)
    • NovaBay Pharmaceuticals Inc (NBY)
    • Oragenics Inc (OGEN)
    • Palatin Technologies Inc (PTN)
    • Theriva Biologics Inc (TOVX)

VYNE Therapeutics Dividend Yield

VYNE Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 0%
Revenue: 46.67% 10%

Analyst Recommendations

Buy Recommendations: 2
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 5.58
Upside from Last Price: 76.69%

Major Shareholders

  • How many VYNE shares are owned by institutional investors?
    9.5M VYNE shares are owned by institutional investors
  • How many VYNE shares are owned by insiders?
    2.3M VYNE shares are owned by insiders